Please use this identifier to cite or link to this item:
Title: The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Austin Authors: Bach, Leon A;Cooper, Mark E;O'Brien, R C;Jerums, George 
Affiliation: Endocrine Unit, Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Jan-1990
Publication information: Journal of the American Geriatrics Society; 38(1): 10-4
Abstract: Epidemiological evidence suggests that elevated serum cholesterol, especially the low density lipoprotein (LDL) fraction, the total/high density lipoprotein (HDL)-cholesterol ratio, and the LDL/HDL-cholesterol ratio, remains a risk factor for atheromatous disease up to the age of 79 years. We studied the efficacy and tolerability of simvastatin, an HMG CoA reductase inhibitor, in 20 patients aged 65 to 75 years with clinical evidence of atheromatous disease. After four weeks of treatment, there was a 29% fall in LDL-cholesterol levels (P less than .01 vs placebo) with low dose simvastatin and a 38% fall with high dose simvastatin (P less than .001 vs placebo). Similar falls were seen in total cholesterol levels and the LDL/HDL-cholesterol and total/HDL-cholesterol ratios. Apoprotein B levels decreased by approximately 20% with both doses (P less than .05 vs placebo). In an open extension of the study, the decreases in lipid parameters were sustained for a further 48 weeks of treatment with doses of simvastatin ranging from 10 to 40 mg. Two patients required the addition of cholestyramine. Although a small study like this cannot establish safety and tolerance, side effects were minor and did not require stopping therapy in any patient. Simvastatin is an effective cholesterol lowering agent in older patients.
Gov't Doc #: 2404052
Journal: Journal of the American Geriatrics Society
Type: Journal Article
Subjects: Aged
Anticholesteremic Agents.administration & dosage.adverse effects.therapeutic use
Arteriosclerosis.blood.drug therapy
Cataract.chemically induced.drug therapy
Cholesterol, HDL.blood
Cholesterol, LDL.blood
Drug Administration Schedule
Follow-Up Studies
Hypercholesterolemia.blood.drug therapy
Lovastatin.administration & dosage.adverse effects.analogs & derivatives.therapeutic use
Randomized Controlled Trials as Topic
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 16, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.